PURPOSE: Beagle dogs are used to study oral pharmacokinetics and guide development of drug formulations for human use. Since mechanistic insight into species differences is needed to translate findings in this species to human, abundances of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) drug metabolizing enzymes have been quantified in dog liver and intestine. METHODS: Abundances of enzymes were measured in Beagle dog intestine and liver using selected reaction monitoring mass spectrometry. RESULTS: Seven and two CYPs were present in the liver and intestine, respectively. CYP3A12 was the most abundant CYP in both tissues. Seven UGT enzymes were quantified in the liver and seven in the intestine although UGT1A11 and UGT1A9 were present only in the intestine and UGT1A7 and UGT2B31 were found only in the liver. UGT1A11 and UGT1A2 were the most abundant UGTs in the intestine and UGT2B31 was the most abundant UGT in the liver. Summed abundance of UGT enzymes was similar to the sum of CYP enzymes in the liver whereas intestinal UGTs were up to four times more abundant than CYPs. The estimated coefficients of variation of abundance estimates in the livers of 14 donors were separated into biological and technical components which ranged from 14 to 49% and 20 to 39%, respectively. CONCLUSIONS: Abundances of canine CYP enzymes in liver and intestine have been confirmed in a larger number of dogs and UGT abundances have been quantified for the first time. The biological variability in hepatic CYPs and UGTs has also been estimated.
PURPOSE:Beagle dogs are used to study oral pharmacokinetics and guide development of drug formulations for human use. Since mechanistic insight into species differences is needed to translate findings in this species to human, abundances of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) drug metabolizing enzymes have been quantified in dog liver and intestine. METHODS: Abundances of enzymes were measured in Beagle dog intestine and liver using selected reaction monitoring mass spectrometry. RESULTS: Seven and two CYPs were present in the liver and intestine, respectively. CYP3A12 was the most abundant CYP in both tissues. Seven UGT enzymes were quantified in the liver and seven in the intestine although UGT1A11 and UGT1A9 were present only in the intestine and UGT1A7 and UGT2B31 were found only in the liver. UGT1A11 and UGT1A2 were the most abundant UGTs in the intestine and UGT2B31 was the most abundant UGT in the liver. Summed abundance of UGT enzymes was similar to the sum of CYP enzymes in the liver whereas intestinal UGTs were up to four times more abundant than CYPs. The estimated coefficients of variation of abundance estimates in the livers of 14 donors were separated into biological and technical components which ranged from 14 to 49% and 20 to 39%, respectively. CONCLUSIONS: Abundances of canineCYP enzymes in liver and intestine have been confirmed in a larger number of dogs and UGT abundances have been quantified for the first time. The biological variability in hepatic CYPs and UGTs has also been estimated.
Authors: Magang Shou; Ryan Norcross; Grit Sandig; Ping Lu; Yinghe Li; Yuh Lin; Qin Mei; A David Rodrigues; Thomas H Rushmore Journal: Drug Metab Dispos Date: 2003-09 Impact factor: 3.922
Authors: Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court Journal: Drug Metab Dispos Date: 2016-10-06 Impact factor: 3.922
Authors: Tania E Perez Jimenez; Butch Kukanich; Hyun Joo; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court Journal: Drug Metab Dispos Date: 2018-10-26 Impact factor: 3.922
Authors: Oliver J D Hatley; Christopher R Jones; Aleksandra Galetin; Amin Rostami-Hodjegan Journal: Biopharm Drug Dispos Date: 2017-02-14 Impact factor: 1.627
Authors: Daniel Scotcher; Sarah Billington; Jay Brown; Christopher R Jones; Colin D A Brown; Amin Rostami-Hodjegan; Aleksandra Galetin Journal: Drug Metab Dispos Date: 2017-03-07 Impact factor: 3.922